In the BOLERO-@ trial , everolimus ( EVE ) , an inhibitor of mammalian target of rapamycin , demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane ( EXE ) in postmenopausal women with hormone receptor-positive ( HR ( + ) ) advanced breast cancer .